Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 15/20 | 0.71 |
| ▸ | EDNRB | P24530 | 8/20 | 0.63 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | DHPS | P49366 | 1/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.57 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8399577 | 0.92 | EDNRA (0.61) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL14097339 | 0.92 | EDNRA (0.64) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7588725 | 0.91 | EDNRA (0.79) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7600932 | 0.90 | EDNRA (0.70) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7305595 | 0.90 | EDNRA (0.74) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL8327615 | 0.88 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL15218752 | 0.88 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7586114 | 0.87 | EDNRA (0.75) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL8321011 | 0.86 | EDNRA (0.76) | EDNRAEDNRB | |
| SCHEMBL7592200 | 0.86 | EDNRA (0.67) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0768304-B1 | N-(Pyrimidinyl)-benzenesulfonamides as medicaments | HOFFMANN LA ROCHE (CH) | 2002-05-22 | — | — | EP | claimed |
| US-5856484-A | Sulfonylaminopyrimidine carboxylic acid derivatives having endothelin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | claimed |
| US-20210077562-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB THERAPEUTICS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190314444-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019191721-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20100173872-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173872-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-06 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| US-5856484-A | Sulfonylaminopyrimidine carboxylic acid derivatives having endothelin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | EDNRA 429/4885EDNRB 502/4885ABCC3 1458/4885 |
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | OPRK1, OPRL1, OPRM1 | EDNRA 6/4885EDNRB 8/4885ABCC3 2300/4885 |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | COX15, PTGER3, PTGER4 | EDNRA 11/4885EDNRB 8/4885ABCC3 3922/4885 |
| US-20100173872-A1 | Method and Composition for Treating Alzheimer's Disease and Dementias of Vascular Origin | PSEN1, PSEN2, CHAT | EDNRA 11/4885EDNRB 7/4885ABCC3 1440/4885 |
| US-20190314444-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | EDNRB, EDNRA, LTB4R | EDNRA 2/4885EDNRB 1/4885ABCC3 1774/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885ABCC3 1702/4885 |
| US-20210077562-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | EDNRB, EDNRA, LTB4R | EDNRA 2/4885EDNRB 1/4885ABCC3 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.